Canadian pharmaceutical firm Draxis Health posted a 19% increase in its fiscal 2006 second-quarter (end-June 30) revenues of $24.3 million (U.S.), compared with the $20.5 million shown in the same period of fiscal 2005.
Second-quarter net income for the Mississauga, Ontario-based developer also showed double-digit growth to $3.6 million, a 52% surge compared with the $2.4 million of net income booked for the same period last year.
The company noted that radiopharmaceutical product sales grew 13% for the second quarter, driven primarily by increased sales of sodium iodide I-131 products in the U.S.
By AuntMinnie.com staff writers
August 10, 2006
Related Reading
Draxis joins Nasdaq Global Select Market, July 5, 2006
Draxis posts Q1 downturn, May 11, 2006
DraxImage shelves Fibrimage, unveils new generics initiative, March 28, 2006
Draxis shows 2005 revenue growth, February 10, 2006
Draxis radiopharmaceutical approved, January 13, 2006
Copyright © 2006 AuntMinnie.com
